Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non‐high‐risk acute lymphoblastic leukemia treated according to the ALL‐MB 2008 protocol

Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non‐high‐risk acute lymphoblastic leukemia treated according to the ALL‐MB 2008 protocol

Abstract Background Quantitative measurement of minimal residual disease (MRD) is the “gold standard” for estimating the response to therapy in childhood B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). Nevertheless, the speed of the MRD response differs for different cytogenetic subgroups....

Full description

Bibliographic Details
Main Authors: Alexander Popov, Guenter Henze, Grigory Tsaur, Oleg Budanov, Julia Roumiantseva, Mikhail Belevtsev, Tatiana Verzhbitskaya, Liudmila Movchan, Svetlana Lagoyko, Liudmila Zharikova, Yulia Olshanskaya, Tatiana Riger, Alena Valochnik, Natalia Miakova, Dmitry Litvinov, Olga Khlebnikova, Olga Streneva, Elena Stolyarova, Natalia Ponomareva, Galina Novichkova, Olga Aleinikova, Larisa Fechina, Alexander Karachunskiy
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:Cancer Medicine
Subjects:
acute lymphoblastic leukemia
flow cytometry
genetic risk groups
minimal residual disease
Online Access:https://doi.org/10.1002/cam4.7172

Internet

https://doi.org/10.1002/cam4.7172

Similar Items